PCSK9 and familial hypercholesterolemia: Therefore, inhibition of PCSK9 is clinically useful for treatment of hypercholesterolemia, and inhibitors of PCSK9 have been FDA-approved as cholesterol-lowering therapeutics (Weinreich and Frishman, 2014).